Glaukos’ iDose TR meets primary goal in phase 4 trial

Press Room

2 hours ago

Close-up of mature patient undergoing detailed eye examination with slit lamp and light at ophthalmology clinic

Glaukos Corp. (GKOS) said that topline phase 4 data for iDose TR (travoprost intracameral implant) for individuals with open-angle glaucoma or ocular hypertension showed that the implant led to a reduction of mean diurnal intraocular pressure (IOP) when administered

Exit mobile version